Caplyta (Lumateperone Tosylate) Patent Expiration, LOE Window & CMS Spending

Caplyta (Lumateperone Tosylate) by Intra-Cellular Therapies: FDA Orange Book core substance LOE 2029-12-01 (last listed 2040-12-10), 0 AB generics, $595.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIntra-Cellular Therapies
FDA Application & PathwayN209500 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2029-12-01
Last Listed Patent or Exclusivity Date2040-12-10
Orange Book Patents (*PED Extensions)23 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$595.9M
2024 Medicare Part D Spend$268.5M
2024 Medicaid Spend$327.4M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.9% 2-yr change)